The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
145 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $107,246,975 in first-year total cost, median $499,860.
Most frequent study sections
- Special Emphasis Panel[ZRG1 RPHB-Y (12)]37
- Special Emphasis Panel[ZRG1 ETTN-H (11)]16
- Special Emphasis Panel[ZRG1 ETTN-A (13)]12
- Special Emphasis Panel[ZRG1 ETTN-G (13)]12
- Special Emphasis Panel[ZRG1 ETTN-S (14)]11
Most frequent institutions
- BIOSENSICS, LLC4
- PRONEUROGEN, INC.3
- TOGETHER SENIOR HEALTH, INC.3
- ALLIED INNOVATIVE SYSTEMS, LLC2
- AMBERGEN, INC2
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2023 | A Novel Algorithm to Identify People with Undiagnosed Alzheimer's Disease and Related Dementias1R44AG082605-01 | BARNES, DEBORAH E.BENJAMIN, CYNTHIA LOUISE | TOGETHER SENIOR HEALTH, INC., NY | $1,535,530 | ZRG1 |
| 2023 | Development of a novel, regenerative therapy to reverse synapse loss in Alzheimer's Disease1R44AG082648-01 | VANDERKLISH, PETER W | SPINOGENIX, INC., CA | $1,419,610 | ZRG1 |
| 2023 | Developing a novel EEG-based index for evaluating amyloid and tau burden in Alzheimer's Disease1R44AG080940-01 | LUCERO, CHE | SPARK NEURO INC., NY | $1,314,973 | ZRG1 |
| 2023 | Stretching their Reach: Robotic Support for Older Individuals with Mild Cognitive Impairment, Early Alzheimer's Dementia, and Mobility Impairments2R44AG072982-02 | EDSINGER, AARONROGERS, WENDY A | HELLO ROBOT INC, CA | $1,279,576 | ZRG1 |
| 2023 | Novel Approaches for Tau PROTAC Drug Discovery2R44AG066271-02A1 | KADIMISETTY, KARTEEK | LIFESENSORS, INC., PA | $1,254,536 | ZRG1 |
| 2023 | Clinical Development Enablement – Long Term Rodent Testing of the Carcinogenic Potential of the Alzheimer’s Disease Drug Candidate T3D-9591R44AG082580-01 | DIDSBURY, JOHN | T3D THERAPEUTICS, INC., NC | $1,249,334 | ZRG1 |
| 2023 | Clinical Decision Support System for Early Detection of Cognitive Decline Using Electronic Health Records and Deep Learning1R44AG081006-01 | DU, JINGCHENGMANION, FRANK J.ZHOU, LI | MELAX TECHNOLOGIES, INC., TX | $1,121,445 | ZRG1 |
| 2023 | Highly sensitive immunoassay for determination of biomarkers for neurodegenerative diseases2R44AG073141-02 | BYSTRYAK, SIMON | ALLIED INNOVATIVE SYSTEMS, LLC, NJ | $977,713 | ZRG1 |
| 2023 | Novel whole-genome analysis methods for Alzheimer's risk prediction2R44AG050366-04 | GREYTAK, ELLEN MCRAE | PARABON NANOLABS, INC., VA | $917,300 | ZRG1 |
| 2023 | Concurrent Aerobic Exercise and Cognitive Training to Prevent Alzheimer's in at-risk Older Adults1R44AG082637-01 | OLOFINBOBA, OLUSALISBURY, DERECK L | MOAI TECHNOLOGIES, LLC, MN | $811,421 | ZRG1 |
| 2023 | Optimization of small molecule SERCA2b activators to inhibit neuron loss in Alzheimer's disease2R44AG062001-04 | DAHL, RUSSELL | NEURODON LLC, IN | $529,129 | ZRG1 |
| 2023 | Novel Intranasal Formulations of Allopregnanolone, a Regenerative Therapeutic for Alzheimer's Disease1R43AG081024-01A1 | BRINTON, ROBERTA EILEENRINEHART, JOHN | NEUTHERAPEUTICS, LLC, AZ | $505,836 | ZRG1 |
| 2023 | A Gesture-Powered Software Platform of Neurologic Music Therapy Games and Puzzles: To Stimulate Neuroplasticity and Prolong Functional Independence in Individuals Diagnosed with Alzheimer's Disease1R43AG081111-01 | GRAY, PETER | OUTLIER TECHNOLOGY, LLC, FL | $504,505 | ZRG1 |
| 2023 | Developing a Personalized and Culturally Responsive Virtual Coach to Engage Persons with Alzheimer's Disease and Related Dementias in Cognitive and Physical Activities1R43AG082546-01 | WANG, EMILY S. | BEAVER HEALTH, INC., CA | $499,952 | ZRG1 |
| 2023 | Inhibition of Complement Pathways with VCP As A Treatment For Alzheimer's Disease1R43AG080890-01 | ZHOU, JIANHUA | INFLAMED, INC., KY | $497,200 | ZRG1 |
| 2023 | VRSingTogether: Digital therapeutic virtual reality tool to mitigate the effects of Alzheimer's Disease (AD) and Alzheimer's-Disease-Related Dementias (ADRD)1R43AG079739-01A1 | HOAGLAND, RICHARD | RALPHVR INC., KY | $452,016 | ZRG1 |
| 2023 | Autonomous Navigating Robot for Detecting Falls and Risk of Falls in Nursing Home Residents with Alzheimer's Disease /ADRD1R43AG082599-01 | MALINSKY, YUVAL | VIGOROUS MIND, INC., MA | $450,000 | ZRG1 |
| 2023 | Development and Evaluation of Portable Compendium of Psychophysical and Physiological Tests for Alzheimer's Disease and Related Dementias (ADRD)1R44AG082621-01 | NWAOKOBIA, CHARLES CHIEDUNWULIA, EVARISTUS AREDDY, VAMSI | EVON MEDICS, LLC, MD | $448,887 | ZRG1 |
| 2023 | Diagnostic aptamer reagents to develop multi-analyte blood test for pre-clinical, mild and moderate Alzheimer's disease1R43AG080844-01 | GAWANDE, BHARAT | APTUS BIOSCIENCES LLC, FL | $445,554 | ZRG1 |
| 2023 | Wicked Smart Pad: Washable Sensorized Bedding for the Prevention and Detection of Moisture Events1R43AG078020-01A1 | TRUTTMANN, ALLISON | WICKED SHEETS, LLC, KY | $342,745 | ZRG1 |
| 2022 | Evaluation of a dual PPAR agonist for treatment of Alzheimer's disease2R42AG065069-03A1 | CARDELLI, JAMES | OLEOLIVE, INC., LA | $1,692,440 | ZRG1 |
| 2022 | Screening ADNI patient cohorts to identify a sub-population that are AD early progressors in validating the prognostic ability of the Alzosure Predict blood test, 6 years in advance of current methods1R44AG078051-01 | KINNON, PAUL | DIADEM US, INC., CA | $1,606,227 | ZRG1 |
| 2022 | The Proactive Screening and diagnosis of mild cognitive impairment and depression in patients aged 65 and over: An Implementation Study1R44AG079760-01 | GLENN, SHENLY | MIRO HEALTH INC, CA | $1,491,441 | ZRG1 |
| 2022 | Photocleavable Mass-Tags for Spatial Multiomics of Alzheimer’s Brain Tissue1R44AG078097-01 | LIM, MARK | AMBERGEN, INC, MA | $1,354,952 | ZRG1 |
| 2022 | PhytoSERM for Menopausal Hot Flashes and Sustained Brain Health1R44AG078102-01A1 | BRINTON, ROBERTA EILEENRINEHART, JOHN | NEUTHERAPEUTICS, LLC, AZ | $1,337,363 | ZRG1 |
| 2022 | Rapid saliva test for noninvasive diagnostic screening of MCI and dementia1R44AG078044-01 | ETTENHOFER, MARKNATION, DANIEL ASOUTHERN, SARKA OLIVERA | GAIA MEDICAL INSTITUTE, INC., CA | $1,282,078 | ZRG1 |
| 2022 | Automated, Assistive, Non-Contact Sleep Quality Monitor for Individuals with Alzheimer Disease2R44AG058339-02A1 | KABLAN, JOHN | INNOVATIVE DESIGN LABS, INC., MN | $1,281,557 | ZRG1 |
| 2022 | Caring4Caregivers: A theory-driven mobile solution to promote self-care and well-being among caregivers of individuals with Alzheimer’s andrelated dementias1R44AG076345-01 | EVERS, KERRY | PRO-CHANGE BEHAVIOR SYSTEMS, INC., RI | $1,278,235 | ZRG1 |
| 2022 | Preclinical Characterization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease2R44AG061995-02A1 | GREENBERG, MILTON L | VIVREON BIOSCIENCES, LLC, CA | $1,276,596 | ZRG1 |
| 2022 | Amadorins for Ameliorating Alzheimer's Disease and Related Dementias (ADRD)1R44AG079696-01 | KHALIFAH, RAJA G | PRAETEGO, INC., NC | $1,259,042 | ZRG1 |
| 2022 | Development of a Remotely Deliverable Cognitive Assessment Sensitive to Early Stage Mild Cognitive Impairment.1R44AG074818-01A1 | KALLESTRUP, PETER | I-FUNCTION, INC., FL | $1,251,954 | ZRG1 |
| 2022 | A Multi-Modal Remote Monitoring Platform for Frontotemporal Lobar Degeneration Syndromes1R44AG080861-01 | PANTELYAT, ALEXANDER Y.VAZIRI, ASHKANWILLS, ANNE-MARIE | BIOSENSICS, LLC, MA | $1,250,000 | ZRG1 |
| 2022 | A light exposure tracker designed to improve the circadian entrainment for Alzheimer Disease patients2R44AG060857-05 | PAGE, ERIK | BLUE IRIS LABS, INC., CA | $1,248,510 | ZRG1 |
| 2022 | A Diagnostic Test for Dementia with Lewy Bodies1R44AG076072-01 | LEVINE, TODD | CND LIFE SCIENCES, INC., AZ | $1,239,804 | ZRG1 |
| 2022 | A 26-week rat toxicity study and efficacy and biomarker studies in Tau-APP Alzheimer's mouse model to support a Phase 1b clinical study1R44AG077991-01A1 | MOE, JAMES G. | OLIGOMERIX, INC, NY | $1,124,972 | ZRG1 |
| 2022 | Multi-modal machine learning detection and tracking of traumatic brain injury neurodegeneration and its differentiation from Alzheimer's disease2R44AG060861-02 | LUKIC, ANA S | ADM DIAGNOSTICS, INC., IL | $1,044,935 | ZRG1 |
| 2022 | Multiplexed immunoassay for building patient-specific molecular profiles of CSF amyloid beta and TAU1R44AG080889-01 | ANTHONYMUTHU, TAMIL SELVAN | ADEPTRIX CORPORATION, MA | $1,040,019 | ZRG1 |
| 2022 | New BDNF Nanoparticles for Early Treatment of Alzheimer's Disease2R44AG058343-04 | VITALIANO, FRANCOVITALIANO, GORDANA D. | EXQOR TECHNOLOGIES, INC., MA | $1,006,687 | ZRG1 |
| 2022 | Augmem: A Novel Digital Cognitive Assessment for the Early Detection of Alzheimer's Disease1R44AG079718-01 | GILPIN, ADELE | AUGNITION LABS LLC, NY | $1,004,853 | ZRG1 |
| 2022 | Multi-site longitudinal Integrated Neurocognitive and Sleep-Behavior Profiler for the Endophenotypic Classification of Dementia Subtypes (INSPECDS)2R44AG050326-03A1 | BERKA, CHRIS | ADVANCED BRAIN MONITORING, INC., CA | $999,922 | ZRG1 |
| 2022 | Amyloid-Beta and Tau/Glycosaminoglycan Dual Inhibitor for Alzheimer's Disease2R44AG056231-03A1 | GREGOR, PAUL | GISMO THERAPEUTICS, INC., NY | $983,932 | ZRG1 |
| 2022 | Validation of a Novel Magnetic Resonance Imaging (MRI) Technology for both Diagnostic Screening and Quantification of Brain Vascular Physiology in Alzheimer's-Disease-Related Dementias1R43AG079732-01 | GHARAGOUZLOO, CODI AMIR | IMAGINOSTICS, INC., FL | $915,931 | ZRG1 |
| 2022 | Fluorescent IRE Sensor for Synucleinopathy Drug Discovery1R44NS130946-01 | SHEN, WEN | LUCERNA, INC., NY | $853,817 | ZRG1 |
| 2022 | A novel platform to facilitate provider adoption of cognitive care planning1R44AG078006-01 | HUANG, BIN | BRAINCHECK, INC., TX | $765,628 | ZRG1 |
| 2022 | Care Assistant for Family Caregivers of Persons with Dementia During Out of the Home Activities2R42AG058336-02A1 | ANDERSON, SHANE M. | KORONIS BIOMEDICAL TECHNOLOGIES CORPORAT, MN | $731,897 | ZRG1 |
| 2022 | BMS-984923 Non-Clinical Development to Support Phase 2 Trials1R44AG077984-01A1 | SIEGERT, TIMOTHY R | ALLYX THERAPEUTICS INC., CT | $680,220 | ZRG1 |
| 2022 | Home Sleep Therapy System for Mild Cognitive Impairment1R44AG077965-01A1 | TUCKER, DON M | BRAIN ELECTROPHYSIOLOGY LABORATORY COMPANY, LLC, OR | $555,043 | ZRG1 |
| 2022 | Development of Blood-based Circular RNA Biomarkers for Alzheimer's Disease1R43AG076106-01A1 | COLLENS, JULIE | VIVID GENOMICS, INC., CA | $508,467 | ZRG1 |
| 2022 | RestEaze: A Novel Wearable Device and Mobile Application to Improve the Diagnosis and Management of Restless Legs Syndrome in Patients with Alzheimer's Disease1R43AG076092-01 | BROOKS, JUSTIN | TANZEN MEDICAL, INC., MD | $500,709 | ZRG1 |
| 2022 | Treatment of Alzheimer's disease by clearing both tau and amyloid beta pathologies1R43AG079671-01 | IQBAL, KHALID | PHANES BIOTECH, INC., PA | $500,000 | ZRG1 |
| 2022 | Digital Transformation to Reduce Social Isolation and Improve the Engagement, Care, and Support of Individuals Living with Alzheimer's Disease and Related Dementias1R43AG076063-01 | KAISER, SCOTT | DETERMINED HEALTH INC., CA | $499,952 | ZRG1 |
| 2022 | Extended-Release Formulation of Mas Receptor Agonists as Novel Therapeutics for Treating Cognitive Impairment in Patients at-risk forAlzheimer's Disease-Related Dementias and Vascular Dementia1R43AG077967-01A1 | HAY, MEREDITHRILEY, JEREMY | PRONEUROGEN, INC., AZ | $499,763 | ZRG1 |
| 2022 | Scale-up Manufacturing and IND Enabling Studies of Extended-Release Formulation of Mas Receptor Agonist for Treating Vascular Cognitive Impairment and Alzheimer's Disease-Related Dementias1R43AG079647-01 | HAY, MEREDITHRILEY, JEREMY | PRONEUROGEN, INC., AZ | $499,598 | ZRG1 |
| 2022 | Single-cell Epigenome Analysis of the Alzheimer's Disease Brain1R43AG079691-01 | HARTL, CHRISTOPHER | EPIGENOME TECHNOLOGIES, INC., CA | $499,475 | ZRG1 |
| 2022 | Novel regulation of autophagic flux for the treatment of Alzheimer's disease1R43AG076052-01 | GREENLEE, WILLIAM J | CERACUITY, INC., MA | $499,272 | ZRG1 |
| 2022 | Development and Validation of Cognitive Status Assessments in Older Adults Utilizing Conversational Agent Technology (CAT) Delivered on Smart Displays - the CAUCAT Study1R43AG076078-01 | WILLIAMS, RANDALL | WELLSAID.AI, LLC, IL | $498,925 | ZRG1 |
| 2022 | PET Imaging of Damaging Neuroinflammation in Alzheimer's Disease1R44AG079734-01 | LARSON, ANDREW CHRISTIAN | EINSENCA INC., DE | $497,602 | ZRG1 |
| 2022 | Promoting adult hippocampal neurogenesis using antisense oligonucleotides as an Alzheimer's disease therapy1R43AG078093-01 | VALAT, ANNE | BOLDEN THERAPEUTICS, INC., RI | $497,550 | ZRG1 |
| 2022 | Accessible Eye Tracking Solution for Assessment of Cognitive Deficits in Alzheimer's Disease1R43AG076140-01 | YOO, HERBERT | SENAPTEC INC., OR | $497,154 | ZRG1 |
| 2022 | Ensuring medication ingestion without altering existing medication regimen1R43AG073011-01A1 | CARNES, TONY CHRIS | ETECTRX, INC., FL | $496,388 | ZRG1 |
| 2022 | Brain-penetrant chemical disaggregators of tau fibrils as therapeutics for Alzheimer's Disease1R43AG073018-01A1 | APOSTOL, MARCIN | ADRX, INC., CA | $476,551 | ZRG1 |
| 2022 | Community-based Brain Health Program to Address Dementia Risk (C-BBHP)1R43AG074756-01A1 | VANVLEET, THOMAS | POSIT SCIENCE CORPORATION, CA | $465,294 | ZRG1 |
| 2022 | CUSTOMIZABLE TRAINING SOFTWARE FOR PROFESSIONAL ALZHEIMER DIRECT CARE PROVIDERS1R44AG076093-01 | FOSTER, NORMAN LOUIS | PROACTIVE MEMORY SERVICES, INC., UT | $456,315 | ZRG1 |
| 2022 | eREACH - Expanding Research and Recruitment by Adults through Community Health workers that automating screenings and referrals plus improving communication and health information delivery1R43AG076186-01 | MA, TONY XUYEN | BENTEN TECHNOLOGIES, INC., VA | $456,161 | ZRG1 |
| 2022 | Optimization of an at-home continuous multi-domain monitoring and assessment system to improve Alzheimer's and related disorders clinical trials1R44AG076067-01 | FRYE, LAWRENCE J | LIFE ANALYTICS, INC., CA | $453,828 | ZRG1 |
| 2022 | Development of a Blood-based Test for Identifying Synucleinopathy in Patients with Dementia1R44NS130864-01 | EITAN, EREZ | NEURODEX INC, MA | $449,999 | ZRG1 |
| 2022 | A physiologically relevant pre-clinical drug screening platform for Alzheimer's Disease and Traumatic Brain Injury with integrated stretchable microelectrodes1R44AG079777-01 | GRAUDEJUS, OLIVER | BMSEED, LLC, AZ | $449,997 | ZRG1 |
| 2022 | Smart driving technology for non-invasive detection of age-related cognitive decline1R43AG078063-01 | FORZANI, ERICA SILVIATSOW, FRANCIS | TF HEALTH CORPORATION, AZ | $449,954 | ZRG1 |
| 2022 | An assistive-technology based Caregiver Training Program (CTP) to enhance caregiver effectiveness, well-being, and quality of life, which will improve overall care for individuals living with AD/ADRD.1R44AG076256-01A1 | GOLDEN, MATTHEW | MAPHABIT, INC., GA | $449,826 | ZRG1 |
| 2022 | Enhancing Social Engagement through Online Gameplay for Older Adults with and without Mild Cognitive Impairment1R44AG078009-01 | GANDY COLEMAN, MARIBETHMYERS, DILLONVICKERS, KAYCI | POTLUCK, LLC, VA | $449,777 | ZRG1 |
| 2022 | SynchronyGamma: A Music-Based Intervention for Alzheimer's and Mild Cognitive Impairment1R43AG078012-01 | LARGE, EDWARD WLOUI, PSYCHE | OSCILLOSCAPE, LLC, CT | $449,695 | ZRG1 |
| 2022 | Preventing Medication Mismanagement in People Living with Dementia through Automated Medication Dispensing with Facial Recognition and Video Observation1R43AG077737-01 | GELLMAN, CHARLES | HIDO TECHNOLOGIES, INC., CA | $449,609 | ZRG1 |
| 2022 | Developing Novel REV-ERB Agonists for the Treatment of Neuroinflammation in Alzheimer's Disease1R41AG079778-01A1 | CRESAP, MICHELE | PELAGOS PHARMACEUTICALS, INC., TX | $449,482 | ZRG1 |
| 2022 | Virtual Reality Cognitive Therapy forAlzheimer's Disease1R43AG076169-01 | MASOOD, RAZI | CLARITYTEK, INC., MN | $445,324 | ZRG1 |
| 2022 | Automated System for Accurate Determination of Activities of Daily Living for Independently-Living Persons with Alzheimers Disease and Related Dementias1R43AG076113-01A1 | SHEIKH, SUNEEL ISMAIL | ASTER LABS, INC., MN | $439,460 | ZRG1 |
| 2022 | Development of a brain penetrating single-chain antibody selectively targeting three repeat tau protein as a new treatment for frontotemporal dementia1R43NS125810-01 | SAITO, ERIN | 3RT INNOVATIONS, CA | $433,405 | ZRG1 |
| 2022 | Identifying Regulators of Cellular Aging that can Prevent Alzheimer's Disease1R43AG076101-01 | DORANZ, BENJAMIN J | INTEGRAL MOLECULAR, PA | $358,588 | ZRG1 |
| 2022 | Decision support tool that uses novel feature extraction and machine learning approaches for early identification of Alzheimer's patients who are candidates for palliative and/or hospice care.1R43AG076191-01 | VASUDEVAN, ANANT | RADIAL ANALYTICS, INC., MA | $350,832 | ZRG1 |
| 2022 | Improved carnosic acid congener compounds for Alzheimer’s disease1R43AG080911-01 | LARRICK, JAMES WMENDELSOHN, ANDREW R | LARIX BIOSCIENCE, LLC, CA | $326,205 | ZRG1 |
| 2022 | Tau mislocalization assay to screen AD therapeutics using compartmentalized chips1R43AG072985-01A1 | TAYLOR, ANNE MARION | XONA MICROFLUIDICS, LLC, NC | $268,419 | ZRG1 |
| 2022 | All About Me: An Intervention to Ease the Transition to Long-term Care, Build Community, and Improve Quality of Care for Persons with Dementia1R43AG077993-01 | GORZELLE, GREGGSKRAJNER, MICHAEL JOHN | HOPEFUL AGING LLC, MA | $259,010 | ZRG1 |
| 2022 | SAFE at Home: A Service to Provide Social Engagement to Community-Dwelling Persons with Dementia1R43AG075974-01 | SKRAJNER, MICHAEL JOHN | HOPEFUL AGING LLC, MA | $252,014 | ZRG1 |
| 2022 | Quantifying microstructural changes in Alzheimer's disease using Restriction Spectrum Imaging1R44AG076194-01 | ULUG, AZIZ M | CORTECHS LABS, INC., CA | $247,965 | ZRG1 |
| 2021 | BRAIN HEALTH TOGETHER: A LIVE-STREAMING GROUP-BASED DIGITAL PROGRAM2R44AG074727-02 | BARNES, DEBORAH E.BENJAMIN, CYNTHIA LOUISE | TOGETHER SENIOR HEALTH, INC., NY | $1,504,982 | ZRG1 |
| 2021 | An Informatics Platform for Objectively Quantifying Electric Power Wheelchair Usage for those with Alzheimer's Disease, Alzheimer's Disease Related Dementias, and Cognitive Impairments1R44AG074779-01 | BECKER, ADAM | INNOVATIVE DESIGN LABS, INC., MN | $1,337,053 | ZRG1 |
| 2021 | Enabling nationwide AD PET imaging to support most efficient clinical trials by adoption of radically simplified and standardized quality control in commercial production of AD PET tracers.1R44AG071409-01 | ELIZAROV, ARKADIJ | TRACE-ABILITY, INC., CA | $1,256,349 | ZRG1 |
| 2021 | Tele-CF: A practical platform for remote monitoring of cognitive frailty2R44AG061951-02 | NAJAFI, BIJANVAZIRI, ASHKAN | BIOSENSICS, LLC, MA | $1,250,000 | ZRG1 |
| 2021 | Development and Evaluation of Computerized Olfactory Training Program (COT) for Cognitive Decline in Early Alzheimer's Disease (AD)2R44AG061981-03A1 | NWAOKOBIA, CHARLES CHIEDUNWULIA, EVARISTUS ASETH, SUMEET | EVON MEDICS, LLC, MD | $1,247,784 | ZRG1 |
| 2021 | An acoustofluidic device for diagnosing preclinical Alzheimer's disease2R44AG063643-02 | WANG, LIN | ASCENT BIO-NANO TECHNOLOGIES, INC., NC | $1,240,614 | ZRG1 |
| 2021 | Using gamification, predictive analytics, artificial intelligence, and Alexa Voice to optimize user experience for individuals living with AD/ADRD and their caregivers2R44AG065081-03A1 | GOLDEN, MATTHEW | MAPHABIT, INC., GA | $1,189,927 | ZRG1 |
| 2021 | Smartphone phenotype collection for diagnostic screening of mild cognitive impairment2R44AG062072-02A1 | ARMENTROUT, STEVEN L | PARABON NANOLABS, INC., VA | $1,186,625 | ZRG1 |
| 2021 | Development of a PIKFYVE antisense oligonucleotide treatment for FTD1R44NS124454-01 | ALWORTH, SAMUEL VCHANG, WEN-HSUAN | ACURASTEM, INC., CA | $1,014,266 | ZRG1 |
| 2021 | Mindfulness-based Cognitive Coping Mobile App Intervention for caregivers of individuals with Alzheimer's Disease2R44AG058277-02A1 | KAJIYAMA, BRUNO | PHOTOZIG, INC., CA | $980,975 | ZRG1 |
| 2021 | FitMi AD: a safe and motivating computer-guided exercise system for individuals with MCI or mild dementia due to Alzheimer's disease2R44AG063651-02 | ZONDERVAN, DANIEL | FLINT REHABILITATION DEVICES, CA | $717,425 | ZRG1 |
| 2021 | Alzheimer's disease and novel nanotherapeutics exclusively targeting extrasynaptic NMDA receptors1R43AG076088-01 | MOLOKANOVA, ELENA | NEURANO BIOSCIENCE, CA | $500,000 | ZRG1 |
| 2021 | Plasma Assays for NPTX2 in Alzheimer's Disease1R43AG074773-01 | WORLEY, PAUL FXIAO, MEIFANG | COGNEXT DIAGNOSTICS, LLC, MD | $499,999 | ZRG1 |
| 2021 | Feasibility and acceptability of introducing person-centered narratives in an acute care setting for people with Alzheimer's and Dementia1R43AG074775-01 | NEWTON-SMALL, JAYROGERS, STEPHANIE | MEMORYWELL LLC, NM | $499,994 | ZRG1 |
| 2021 | Autonomous Navigating Telepresence Robot for Alleviating Loneliness and Engaging Nursing Home Residents with and without Dementia1R43AG073004-01 | MALINSKY, YUVAL | VIGOROUS MIND, INC., MA | $499,981 | ZRG1 |
| 2021 | Development of Memesto, a wearable repetitive message and music therapy device that senses and reduces agitation in persons with AD/ADRD.1R43AG074725-01 | BANKER, JEFFERY | EDGEWATER SAFETY SYSTEMS LLC, MI | $499,969 | ZRG1 |
| 2021 | Optimization of a Chemokine Receptor Antagonist Peptide as a Synapse Protecting Treatment for Neurodegeneration in Alzheimer's Disease1R43AG074715-01 | RUFF, MICHAEL R | CREATIVE BIO-PEPTIDES, INC., MD | $499,860 | ZRG1 |
| 2021 | Discovery of PDE2A inhibitors to treat memory deficits in mild cognitive impairment and Alzheimer's disease1R43AG071045-01A1 | DU, FUO'DONNELL, JAMES MWANG, WEI | FD NEUROTECHNOLOGIES CONSULTING & SERVICES, INC., MD | $499,784 | ZRG1 |
| 2021 | Drug Discovery Pipeline Targeting Pathologically Leaky Calcium Release Channels in Age-Related Indications1R43AG069582-01A1 | CORNEA, RAZVAN LIVIUTHOMAS, JENNIFER JEWELL | PHOTONIC PHARMA, LLC, MN | $499,443 | ZRG1 |
| 2021 | Interactive Software for Assessing Meaningful Cognitive Function1R43AG074740-01 | FERGUSON, JOHN ERICHUGHES, ADRIANA | ABILITY INTERACTIVE LLC, MN | $499,360 | ZRG1 |
| 2021 | A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS62531R44AG076299-01 | JOHANSSON, JAN | ARTERY THERAPEUTICS, INC., CA | $499,197 | ZRG1 |
| 2021 | A MULTIFACETED DIGITAL HEALTH PLATFORM TO ADVANCE ALZHEIMER'S DISEASE PATIENT MONITORING, SAFETY, CARE, AND RESEARCH.1R43AG072981-01A1 | CORKEY, JON ANDREW | AMISSA, INC., NC | $495,787 | ZRG1 |
| 2021 | Assessing a Novel Virtual Environment that Primes Individuals Living with AD/ADRD to Accomplish Activities of Daily Living.1R43AG071102-01A1 | SALOMON, MANDY | MENTIA DTX, INC., CA | $491,272 | ZRG1 |
| 2021 | An Automated platform for 3D reconstruction and profiling of post-mortem Alzheimer's Disease brains1R43AG076342-01 | RAGAN, TIMOTHY M. | TISSUEVISION, INC., MA | $478,759 | ZRG1 |
| 2021 | A first-in-class orally bioavailable small molecule dual inhibitor targeting NLRP3 and the dopamine transporter to treat AD1R44AG069622-01A1 | BROWN, RUSSELL WAYNEGABBITA, SOMASUNDAR PRASAD | P2D, INC., OH | $470,041 | ZRG1 |
| 2021 | Validating Digital Cognitive Biomarkers to Advance Alzheimer's Drug Development1R43AG074769-01 | SHANKLE, WILLIAM RODMAN | MEDICAL CARE CORPORATION, CA | $455,341 | ZRG1 |
| 2021 | A Humanized Organ Plate Paradigm for High Throughput Alzheimer's disease Therapeutics1R43AG073040-01 | COLLINS, JOHN | BIOPICO, CA | $454,753 | ZRG1 |
| 2021 | Development of a novel anti-neuroinflammatory experimental therapeutic for epilepsy and Alzheimer's risk1R44AG071062-01A1 | KEARNEY, JENNIFER ASHIFRIN, VICTOR | IMMUNOCHEM THERAPEUTICS, LLC, MA | $450,367 | ZRG1 |
| 2021 | Discovery of 12/15-lipoxygenase inhibitors to suppress neuroinflammation and slow disease progression in Alzheimer's disease1R43AG071337-01A1 | SHRADER, WILLIAM DVORAK | ACUREX THERAPEUTICS CORPORATION, CA | $450,060 | ZRG1 |
| 2021 | Development of Aberrant Cdk5 imaging agent for early detection ofAlzheimer's disease pathology and treatment outcome measurement1R43AG069655-01A1 | UPADHYA, SUDARSHAN C | AESTAS PHARMA INC., NC | $450,000 | ZRG1 |
| 2021 | Optimizing Small Molecule Lipoxin-Mimicking FPR2 Agonists for the Treatment of Alzheimers Disease1R43AG072963-01 | GAFFNEY, KEVIN JOHN | RISERX LLC, AZ | $449,931 | ZRG1 |
| 2021 | Development of Nav1.1 Enhancers to Treat Alzheimer's Disease1R44AG071137-01A1 | PLEISS, MICHAEL | CURE NETWORK DOLBY ACCELERATION PARTNERS LLC, CA | $449,821 | ZRG1 |
| 2021 | Automated Contact Tracing System for Rapid High-Accuracy Assessment to Management Dementia Patients and Staff Exposed to Infectious Diseases in Long Term Care Facilities1R44AG072957-01 | SHEIKH, SUNEEL ISMAIL | ASTER LABS, INC., MN | $449,145 | ZRG1 |
| 2021 | LifeBio-ALZ: AI driven digital biomarker engine leveraging natural conversation to widely scale accessibility for early detection and assessment of Alzheimers disease progression1R43AG076341-01 | SANDERS, LISBETH | LIFEBIO INC, OH | $448,462 | ZRG1 |
| 2021 | Auracle: An AI-Enabled Telecare System to Support the Independence and Safety of Individuals with AD/ADRD and Other Dementias1R44AG071211-01A1 | FAUCI, MARK A | GEN-9, INC., CA | $445,911 | ZRG1 |
| 2021 | Development of a technology-enabled care coaching service for families caring for AD/ADRD & a 300-family study to assess the service's impact on CG financial knowledge, efficacy, strain & action.1R44AG074778-01 | CHUNG, JOSEPH | KINTO, MA | $437,367 | ZRG1 |
| 2021 | Circular mimics of Iron-response elements to inhibit ferroptosis1R43NS122654-01 | PICKERING, BRIAN FREDERICK | CHIMERNA THERAPEUTICS INC., NY | $433,356 | ZRG1 |
| 2021 | Discovery of Novel Blood-Brain Barrier Targeting Antibodies for the Treatment of Alzheimer's Disease1R43AG073065-01 | MILENI, MAURO | ABILITA BIO, INC., CA | $432,856 | ZRG1 |
| 2021 | RETAIN: A digital therapeutic for Alzheimer's risk reduction1R44AG071416-01A1 | MCINNIS, MARK | RETAIN HEALTH INC, MA | $430,707 | ZRG1 |
| 2021 | Highly sensitive immunoassay for determination of biomarkers for neurodegenerative diseases1R43AG073141-01 | BYSTRYAK, SIMON | ALLIED INNOVATIVE SYSTEMS, LLC, NJ | $422,885 | ZRG1 |
| 2021 | Prototype Multimedia ADRD Falls Prevention System for Family Caregivers1R43AG071360-01A1 | PANZER, VICTORIA P | BROOKSIDE RESEARCH & DEVELOPMENT COMPANY, WA | $246,663 | ZRG1 |
| 2020 | Safety and Pharmacokinetics of JOTROL for Alzheimer's Disease1R44AG067907-01A1 | HAYWARD, MARSHALL | JUPITER NEUROSCIENCES, INC., FL | $1,764,270 | ZRG1 |
| 2020 | GaitIQ: Establishing a Digital Biomarker of Preclinical Alzheimer's Disease2R44AG060855-02 | JACOB, MINI ELIZABETHMORRIS, RICHARDNICOLELLA, DANIEL P | GAITIQ, LLC, TX | $1,549,244 | ZRG1 |
| 2020 | EXTENDING INDEPENDENCE AND QUALITY OF LIFE FOR PEOPLE WITH ALZHEIMER'S DISEASE OR DEMENTIA THROUGH TELEHEALTH PROGRAM DELIVERY2R44AG059520-02A1 | BARNES, DEBORAH E.BENJAMIN, CYNTHIA LOUISE | TOGETHER SENIOR HEALTH, INC., CA | $1,428,688 | ZRG1 |
| 2020 | Development of a reminiscence therapy online platform with machine learning to increase engagement with people living with dementia and their care partners1R44AG069566-01 | SANDERS, LISBETH | LIFEBIO INC, OH | $1,384,248 | ZRG1 |
| 2020 | Neuro-exergaming for the prevention and remediation of decline due to Alzheimer's disease and related dementias: A clinical trial of the interactive Physical and Cognitive Exercise System (iPACES v3)1R44AG071063-01 | ANDERSON-HANLEY, CAYARCIERO, JOHN P.ARCIERO, PAUL JDUNNAM, MINAMERRILL, DAVID ARTHURPANOS, STELLA ESAULNIER, EMILIE | IPACES, LLC, NY | $1,352,991 | ZRG1 |
| 2020 | Photocleavage Technology for Blood-based Multi-Biomarker Alzheimer's Disease Assay1R44AG067866-01 | LIM, MARK | AMBERGEN, INC, MA | $1,249,958 | ZRG1 |
| 2020 | A non-pharmacological multi-modal therapy to improve sleep and cognition and reduce mild cognitive impairment risk2R44AG056250-03A1 | GARTENBERG, DANIEL | PROACTIVE LIFE, INC., VA | $1,243,520 | ZRG1 |
| 2020 | Optimization of small molecule SERCA2b activators to inhibit neuron loss in Alzheimer's disease2R42AG062001-02A1 | DAHL, RUSSELL | NEURODON LLC, IN | $988,940 | ZRG1 |
| 2020 | Enhancing Quality of Life for Older Adults With and Without MCI through Social Engagement Over Video Technology2R44AG059450-02A1 | MYERS, DILLONROGERS, WENDY A | POTLUCK, LLC, VA | $902,580 | ZRG1 |
| 2020 | Hyperphosphorylated tau aggregation kit to identify tauopathy risk factor2R44AG057274-02 | MORANO, MARIA INES | CAYMAN CHEMICAL COMPANY, INC., MI | $778,104 | ZRG1 |
| 2020 | Mechanistic Validation of Selective Brain-Penetrant HDAC6 Inhibitors as a Disease- Modifying Treatment for Tauopathies including Alzheimer's Disease1R43AG067939-01A1 | SCHROEDER, FREDERICK ALBERT | EIKONIZO THERAPEUTICS, INC., MA | $509,672 | ZRG1 |
| 2020 | LEAD IT! An App to Enable Persons with Early Stage Dementia to Lead Group Activities for Their Peers2R44AG059443-02 | SKRAJNER, MICHAEL JOHN | HEARTHSTONE ALZHEIMER CARE, LTD, MA | $497,150 | ZRG1 |
| 2020 | Innovation in Person-centered Dementia Care and Dementia Assessments: Development of the Care Team Connect App deployed for Home Care Agencies1R43AG071060-01 | POTTEIGER, MICHAEL THOMAS | POTTEIGER CONSULTING SERVICES LLC DBA GENERATION CONNECT, PA | $454,916 | ZRG1 |
| 2020 | TeleExergame: An Interactive Tele-Rehabilitation Platform for Improving Motor Function in Older Adults with Cognitive Deficit1R44AG067909-01 | NAJAFI, BIJANNGUYEN, HUNG P. | BIOSENSICS, LLC, MA | $450,002 | ZRG1 |
| 2020 | Care4AD: A Comprehensive Care Coordination and Management Platform for Alzheimer Disease and Related Dementias1R44AG066360-01A1 | NAJAFI, BIJANVAZIRI, ASHKAN | BIOSENSICS, LLC, MA | $450,000 | ZRG1 |
| 2020 | Development of a Novel Chemokine Receptor Antagonist Peptide as a Synapse Protecting Treatment for Neurodegeneration in Alzheimer's Disease1R43AG071064-01 | RUFF, MICHAEL R | CREATIVE BIO-PEPTIDES, INC., MD | $449,230 | ZRG1 |
| 2020 | Novel Dopaminergic Stimulant Prodrug for the Treatment of Apathy in AD1R44AG066378-01A1 | PATIL, SANDEEPPOTTER, WILLIAM ZEIGLER | PRAXIS BIORESEARCH, LLC, CA | $448,752 | ZRG1 |
| 2020 | Direct activators of protein phosphatase 2A (PP2A) as novel Alzheimer's Disease (AD) therapeutics1R43AG071040-01 | OHLMEYER, MICHAEL | ATUX ISKAY GROUP LLC, NJ | $447,795 | ZRG1 |
| 2020 | Formulation of a Novel Therapeutic for Treating Cognitive Impairment in Patients at-risk for Alzheimer's Disease-Related Dementias and Vascular Contributions to Cognitive Impairment1R43AG069524-01 | CROCKETT, TAMARAHAY, MEREDITHOSSANNA, NINA | PRONEUROGEN, INC., AZ | $439,355 | ZRG1 |
| 2020 | Novel Approaches for PROTAC Drug Discovery1R43AG066271-01A1 | KADIMISETTY, KARTEEK | LIFESENSORS, INC., PA | $397,101 | ZRG1 |
| 2020 | Targeted ultrasound contrast agents for the disruption of Alzheimer's plaques.1R43AG067894-01 | UNGER, WYATT DANIEL | MICROVASCULAR THERAPEUTICS, LLC, AZ | $395,506 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.